Abstract
Twelve men suffering from the primary hyperkinetic heart syndrome (PHHS) displayed palpitation, rapid and forceful heart action, increased pulsations of the large arteries, cardiac systolic murmur, and the following circulatory values (averages): systolic arterial pressure (SAP) = 154 mm Hg; heart rate (HR) = 91 b/min; cardiac index (CI) = 5494 ml/min/m 2; left ventricular mean systolic ejection rate index (MSEJR) = 227 ml/min/m 2; left ventricular mean pre ejection ΔP/Δt = 1.32 mm Hg/msec. A two year followup during which propranolol was administered (80-160 mg/day) revealed good subjective improvement and disappearance of signs of circulatory hyperkinesis. At the end of this period the hemodynamic functions were as follows: SAP = 134; HR = 69; CI = 3489; MSEJR = 171; ΔP/Δt = 0.89. Substitution of placebo for the active drug caused prompt reappearance of symptoms of cardiac overactivity in each patient, and brought the circulatory functions back to these levels: SAP = 157; HR = 96; CI = 5530; MSEJR = 245; ΔP/Δt = 1.33. These findings lend further credence to the concept that the PHHS is, indeed, a definable disease entity; they also document that propranolol ameliorates the symptoms of the disease but is ineffective for the underlying disorder.
| Original language | English |
|---|---|
| Pages (from-to) | 465-474 |
| Number of pages | 10 |
| Journal | American Journal of the Medical Sciences |
| Volume | 270 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 1975 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Long term treatment of the hyperkinetic heart syndrome with propranolol. / Guazzi, M.; Polese, A.; Magrini, F.; Fiorentini, C.; Olivari, M. T.
In: American Journal of the Medical Sciences, Vol. 270, No. 3, 1975, p. 465-474.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Long term treatment of the hyperkinetic heart syndrome with propranolol
AU - Guazzi, M.
AU - Polese, A.
AU - Magrini, F.
AU - Fiorentini, C.
AU - Olivari, M. T.
PY - 1975
Y1 - 1975
N2 - Twelve men suffering from the primary hyperkinetic heart syndrome (PHHS) displayed palpitation, rapid and forceful heart action, increased pulsations of the large arteries, cardiac systolic murmur, and the following circulatory values (averages): systolic arterial pressure (SAP) = 154 mm Hg; heart rate (HR) = 91 b/min; cardiac index (CI) = 5494 ml/min/m 2; left ventricular mean systolic ejection rate index (MSEJR) = 227 ml/min/m 2; left ventricular mean pre ejection ΔP/Δt = 1.32 mm Hg/msec. A two year followup during which propranolol was administered (80-160 mg/day) revealed good subjective improvement and disappearance of signs of circulatory hyperkinesis. At the end of this period the hemodynamic functions were as follows: SAP = 134; HR = 69; CI = 3489; MSEJR = 171; ΔP/Δt = 0.89. Substitution of placebo for the active drug caused prompt reappearance of symptoms of cardiac overactivity in each patient, and brought the circulatory functions back to these levels: SAP = 157; HR = 96; CI = 5530; MSEJR = 245; ΔP/Δt = 1.33. These findings lend further credence to the concept that the PHHS is, indeed, a definable disease entity; they also document that propranolol ameliorates the symptoms of the disease but is ineffective for the underlying disorder.
AB - Twelve men suffering from the primary hyperkinetic heart syndrome (PHHS) displayed palpitation, rapid and forceful heart action, increased pulsations of the large arteries, cardiac systolic murmur, and the following circulatory values (averages): systolic arterial pressure (SAP) = 154 mm Hg; heart rate (HR) = 91 b/min; cardiac index (CI) = 5494 ml/min/m 2; left ventricular mean systolic ejection rate index (MSEJR) = 227 ml/min/m 2; left ventricular mean pre ejection ΔP/Δt = 1.32 mm Hg/msec. A two year followup during which propranolol was administered (80-160 mg/day) revealed good subjective improvement and disappearance of signs of circulatory hyperkinesis. At the end of this period the hemodynamic functions were as follows: SAP = 134; HR = 69; CI = 3489; MSEJR = 171; ΔP/Δt = 0.89. Substitution of placebo for the active drug caused prompt reappearance of symptoms of cardiac overactivity in each patient, and brought the circulatory functions back to these levels: SAP = 157; HR = 96; CI = 5530; MSEJR = 245; ΔP/Δt = 1.33. These findings lend further credence to the concept that the PHHS is, indeed, a definable disease entity; they also document that propranolol ameliorates the symptoms of the disease but is ineffective for the underlying disorder.
UR - http://www.scopus.com/inward/record.url?scp=0016688344&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0016688344&partnerID=8YFLogxK
U2 - 10.1097/00000441-197511000-00007
DO - 10.1097/00000441-197511000-00007
M3 - Article
C2 - 129002
AN - SCOPUS:0016688344
VL - 270
SP - 465
EP - 474
JO - American Journal of the Medical Sciences
JF - American Journal of the Medical Sciences
SN - 0002-9629
IS - 3
ER -